Opinion | Altering Our Vision of Voting
By Charles M. Blow
It has long been clear to me that we are teaching the concept of voting wrong, that we are buying into an idea of false hope and optimism that is easily exploited by those who want fewer people to vote and fewer votes to be counted.
Watch live: Authorities give update on Florida condo collapse as death toll rises
[The stream is slated to start at 6:30 p.m., ET. Please refresh the page if you do not see a player above at that time.]
Subscribe to CNBC on YouTube.
Authorities provided updates on the collapse of a 12-story Florida condominium building in a press conference Wednesday evening.
Authorities addressed the progress of search-and-rescue efforts at the site of the collapse of the Champlain Towers South in Surfside, a town just north of Miami. Miami-Dade County Mayor Daniella Levine Cava said there are 18 confirmed deaths and 145 people unaccounted for.
Authorities are also discussed contingency plans for severe weather, such as tropical hurricanes, that could further stretch responders' painstaking search efforts.
Opinion | Dodge Those Trump Distractions!
By Gail Collins
There really is a lot going on in the country these days. Perfectly OK to ignore totally irrelevant distractions like, say, Donald Trump.
Fred Tesone, architect of Cherry Creek’s football dynasty, dies at age 90
Fred Tesone Bio Box
Cramer's lightning round: Time to buy Zynex stock
- It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
Virgin Galactic: "The class action stuff doesn't bother me as much. What it really is is that it's basically a very expensive stock and I think it had a good run. Let's find others."
Digital Realty: "I would stick with it."
Generac Holdings: "This is a stock that I like very much. Please, do not sell that stock."
Sorrento Therapeutics: "I think it's fine. I mean, look, it's not really a meme stock, but it's one that is — it's got too much hot money in it."
Haemonetics: "I'm a buyer of Haemonetics."
Zynex: "Your analysis is spot on, sir … It's time to buy, not sell your stock."
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the "Mad Money" website? [email protected]
CNN Reporter Booed After Asking Trump About Apology For Capitol Riot
CNN’s Jim Acosta asked Donald Trump whether he would apologize for his involvement in the Jan. 6 riot at the Capitol on Wednesday, but only ended up getting booed by the former president’s followers.
Trump was in Weslaco, Texas, with Gov. Greg Abbott (R), to presumably discuss border issues (but really just to foment more falsehoods about the 2020 presidential election being stolen) when Acosta asked the question.
Since the House had just voted to form a select committee to investigate the attack, Acosta’s question was relevant.
But that didn’t mean Trump would bother to answer it.
Instead, he smirked at Acosta while giving a thumbs-up as his supporters booed Acosta for asking the question.
Considering how doggedly Acosta went after Trump during his time in office, some people sensed a pattern.
FDA Approves Jazz’s Rylaze To Treat Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma
Jazz Pharmaceuticals plc (JAZZ) said that the U.S. Food and Drug Administration has approved Rylaze–asparaginase erwinia chrysanthemi (recombinant)-rywn–for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or ALL or lymphoblastic lymphoma or LBL in pediatric and adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase.
The company expects Rylaze will be commercially available in mid-July.
Rylaze was granted orphan drug designation for the treatment of ALL/LBL by FDA in June 2021. The Biologics Licensing Application approval followed review under the Real-Time Oncology Review program, an initiative of FDA’s Oncology Center of Excellence designed for efficient delivery of safe and effective cancer treatments to patients.
Pre-market Movers: MRIN, AGTC, ORPH, PRTG…
The following are some of the stocks making big moves in Wednesday’s pre-market trading (as of 4.55 A.M.)
In the Green
Marin Software Incorporated (MRIN) is up over 53.80% at $2.63
India Globalization Capital, Inc. (IGC) is up over 41.22% at $2.09
DHI Group, Inc. (DHX) is up over 25.45% at $3.50
Arcus Biosciences Inc. (RCUS) is up nearly 15% at $26.88
Applied Genetic Technologies Corporation (AGTC) is up over 13.43% at S4.73
Uxin Limited (UXIN) is up over 8.29% at $4.04
Orphazyme A/S (ORPH) is up over 11.16% at $8.27
In the Red
Portage Biotech Inc. (PRTG) is down over 23.19% at $26.73
Daqo New Energy Corp. (DQ) is down over 11.31% at $51.51
Entera Bio Ltd. (ENTX) is down over 3.54% at $6.27
Adial Pharmaceuticals, Inc. (ADIL) is down over 3.74% at $2.83
BEST Inc. (BEST) is down over -4.42% at $1.73